Oesophageal cancer

Research from the International Cancer Benchmarking Partnership has found a link between cancer policy consistency over time and survival for six cancer types

Researchers have found a drug that targets the tumour microenvironment that could improve treatment for certain cancers. But it might not be the kind of drug you expect. 

Barrett’s oesophagus affects around 1 in every 100 to 200 people in the UK, and, for a small number of people, can develop into oesophageal cancer. But the origins of the condition have remained a mystery for decades, until now.

The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer.

The Scottish Medicines Consortium (SMC) has approved the immunotherapy drug nivolumab (Opdivo) for some patients with advanced oesophageal cancer.

Our researchers have developed specialised cameras to detect cancer cells that can be hard for both surgical cameras and the naked eye to spot.

Cancer Research UK-funded researchers have developed a tool to help experts diagnose a condition that can increase the risk of developing oesophageal cancer.

Looking at the latest results from the BEST3 trial, analysing the ‘sponge-on-a-string’ test to detect oesophageal cancer earlier.

An immunotherapy drug could prove just as effective as chemotherapy in prolonging the lives of patients with advanced cancers of the stomach or food pipe.

Older patients with advanced oesophageal and stomach cancers might benefit from low dose treatment, according to our unpublished clinical trial results.